CID 65370

Base Information

• Chemical Name: CID 65370
• CAS No.: 28704-27-0
• Molecular Formula: C23H41N5O11
• Molecular Weight: 563.59854
• DSSTox Substance ID: DTXSID50182865
• NCI Thesaurus Code: C87680
• RXCUI: 214582
• Mol file: 28704-27-0.mol

Synonyms:(L-tyrosine-L-glutamic acid)-poly(DL-alanine)-poly(L-lysine);(T,G)-A-L;(Tyr-Tyr-Glu-Glu)-poly(DL-Ala)-poly(Lys);Cop 1 (polymer);copolymer I (synthetic peptide);GLAT copolymer;multideterminant antigen (T,G)-A-L;poly-L-(Tyr,Glu)-poly-DL-Ala-poly-L-Lys;synthetic peptide copolymer I;TGAL copolymer

Chemical Property of CID 65370

Chemical Property:

• Vapor Pressure: 1.27E-06mmHg at 25°C
• Boiling Point: 385.2°Cat760mmHg
• Flash Point: 186.7°C
• PSA: 336.83000
• Density: g/cm³
• LogP: 2.05670
• Storage Temp.: −20°C
• Hydrogen Bond Donor Count: 11
• Hydrogen Bond Acceptor Count: 16
• Rotatable Bond Count: 13
• Exact Mass: 563.28025714
• Heavy Atom Count: 39
• Complexity: 488

Purity/Quality:

99%, ^*data from raw suppliers

Poly(Ala, Glu, Lys, Tyr) 6:2:5:1 hydrobromide Ala:Glu:Lys:Tyr (6:2:5:1), mol wt 20,000-30,000 ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CC(C(=O)O)N.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O)O)N
• Isomeric SMILES: C[C@@H](C(=O)O)N.C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.C(CCN)C[C@@H](C(=O)O)N.C(CC(=O)O)[C@@H](C(=O)O)N
• Description: Copaxone was launched in Israel and the US for treatment of relapsingremitting multiple sclerosis. The amino acid polymer is prepared from the Ncarboxyanhydrides of Tyr, Ala, γ-benzylglutamate and ε,N-trifluoroacetyllysine followed by deprotection. Structurally, the random polymer, with a residue molar ratio of 6.0:1.9:4.7:1.O=Ala:Glu:Lys:Tyr, simulates myelin basic protein (MBP). This gives it immunomodulating and immunosuppressive activity (antigen specific so not a general immunosuppressive). The mechanism involves binding to MHC class Ⅱ (I-A/DR) molecules which results both in competition with myelin antigens for T-cell activation and in induction of specific suppressor cells of the Th2 type. Therefore, the antigenspecific interaction gives rise to a reduced probability of long-term damage to the immune system. The competition with MBP and other myelin-associated antigens inhibits T-cell responses to MBP, and the binding occurs with high efficiency, fast rates and is non-species specific. It resulted in a 29% reduction in relapse rate and is most effective in patients with less accumulated neurologic disability.